Dashboard
Manage Tickers

NRBO NEURO BIOSCIENCE INC

OTC


$ 0.00 (33.33 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.0012
-- x --
-- x --
-- - --
$ 0.00 - $ 0.02
270,270
na
nm
$ 13.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

neurobo-pharmaceuticals-rebrands-as-metavia-reflecting-focus-on-cardiometabolic-diseases-nasdaq-ticker-changes-to-mtva-on-nov-29-ahead-of-key-clinical-milestones-and-mash-therapy-development
NeuroBo Pharmaceuticals Rebrands As MetaVi...
11/18/2024 13:05:04

watching-neurobo-pharmaceuticals-zacks-small-cap-research-gives-stock-22-price-valuation
Watching NeuroBo Pharmaceuticals; Zacks Sm...
11/13/2024 17:58:17

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_NRBO_Bautz.pdf

neurobo-pharmaceuticals-q3-2024-gaap-eps-055-beats-073-estimate
NeuroBo Pharmaceuticals Q3 2024 GAAP EPS $...
11/07/2024 13:23:04

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate ...

neurobo-pharmaceuticals-completes-last-patient-in-the-phase-2a-trial-evaluating-da-1241-for-treatment-of-mash
NeuroBo Pharmaceuticals Completes Last Pat...
11/04/2024 13:05:13

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
10/16/2024 12:10:05

neurobo-pharmaceuticals-reports-top-line-results-from-part-1-of-phase-1-trial-for-da-1726-in-obesity-treatment-showing-favorable-safety-and-dose-linear-pharmacokinetics-with-part-2-data-expected-q1-2025
NeuroBo Pharmaceuticals Reports Top-Line R...
09/30/2024 12:04:02

neurobo-pharmaceuticals-q2-eps-185-misses-112-estimate
NeuroBo Pharmaceuticals Q2 EPS $(1.85) Mis...
08/14/2024 12:15:51

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimat...

neurobo-pharmaceuticals-completes-enrollment-for-single-ascending-dose-sad-part-1-of-phase-1-trial-for-obesity-treatment-da-1726-no-significant-issues-encountered-enabling-accelerated-start-to-multiple-ascending-dose-mad-part-2-top-line-data-for-sad-expected-in-q3-2024-mad-data-in-q1-2025
NeuroBo Pharmaceuticals Completes Enrollme...
08/13/2024 12:04:02

neurobo-pharmaceuticals-together-with-dong-a-st-and-immunoforge-announces-joint-research-agreement-to-develop-a-long-acting-once-monthly-formulation-of-da-1726-for-the-treatment-of-obesity-financial-terms-of-the-agreement-were-not-disclosed
NeuroBo Pharmaceuticals Together With Dong...
08/06/2024 12:22:54

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Tim...

neurobo-pharmaceuticals-announces-joint-research-agreement-with-dong-a-st-co-ltd-and-immunoforge-to-develop-long-acting-once-monthly-formulation-of-da-1726-for-treatment-of-obesity
NeuroBo Pharmaceuticals Announces Joint Re...
08/06/2024 12:22:51

neurobo-pharmaceuticals-shares-are-trading-higher-after-the-company-signed-an-exclusive-license-agreement-providing--mthera-pharma-co-with-the-rights-to-nb-01
NeuroBo Pharmaceuticals shares are trading...
07/30/2024 12:03:59

neurobo-pharmaceuticals-signs-exclusive-license-agreement-providing-mthera-pharma-co-with-rights-to-nb-01
NeuroBo Pharmaceuticals Signs Exclusive Li...
07/30/2024 12:03:06

watching-neurobo-pharmaceuticals-zacks-small-cap-research-gives-stock-22-price-valuation
Watching NeuroBo Pharmaceuticals; Zacks Sm...
07/01/2024 18:13:35

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_07012024_NRBO_Bautz.pdf

neurobo-pharmaceuticals-doses-first-patient-in-mad-part-2-of-phase-1-trial-for-da-1726-in-obesity-treatment-top-line-data-for-part-1-expected-q3-2024-part-2-in-q1-2025-planned-part-3-to-assess-weight-loss-at-24-weeks-70m-financing-to-fund-ongoing-clinical-development
NeuroBo Pharmaceuticals Doses First Patien...
06/26/2024 13:08:02

neurobo-pharmaceuticals-and-2-other-penny-stocks-insiders-are-buying
NeuroBo Pharmaceuticals And 2 Other Penny ...
06/26/2024 12:48:53

dong-a-st-10-buys-254m-shares-of-neurobo-pharmaceuticals-at-avg-price-of-313-total-value-of-79643789
Dong-A ST (10%+) Buys 2.54M Shares of Neur...
06/25/2024 20:24:11

- Form4

neurobo-pharmaceuticals-entered-into-definitive-agreement-for-up-to-70m-concurrent-private-placement-and-registered-direct-offering-of-4325701-shares-at-393share
NeuroBo Pharmaceuticals Entered Into Defin...
06/24/2024 12:03:17

reported-earlier-neurobos-novel-drug-shows-results-for-weight-loss-at-ada-2024
Reported Earlier, NeuroBo's Novel Drug Sho...
06/24/2024 07:05:59

 NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiomet...

neurobo-pharmaceuticals-stock-slides-despite-animal-study-showing-wegvoy-liver-fibrosis-success
NeuroBo Pharmaceuticals Stock Slides Despi...
05/22/2024 14:55:00

NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
05/22/2024 12:06:41

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION